AI assistant
aTYR PHARMA INC — Director's Dealing 2023
Feb 6, 2023
34337_dirs_2023-02-06_a4838f83-e4d9-4882-bae8-254e5afb6b6b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2023-02-03
Reporting Person: DENYES NANCY (General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-03 | Common stock | M | 2688 | — | Acquired | 7079 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-03 | Restricted Stock Unit | $ | M | 2688 | Disposed | Common Stock (2688) | Direct |
Footnotes
F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2: Restricted stock units convert into common stock on a one-for-one basis.
F3: Includes 944 shares acquired under that Company's 2015 Employee Stock Purchase Plan on November 15, 2022.
F4: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.